At ZipBio, we are committed to developing first- and best-in-class therapeutics
Through our proprietary generative AI platform, ZipBio pioneers the development of innovative therapeutics across multiple therapeutic areas. Our internal pipeline is focused on ophthalmology, featuring several preclinical programs aimed at redefining treatment standards. Additionally, we are expanding our impact by collaborating with external partners to develop therapies in other therapeutic areas.
Ophthalmology
The field of ophthalmology encompasses several prevalent diseases with significant unmet therapeutic needs. The unique combination of complex pathophysiology, invasive routes of administration, and challenging ocular anatomy presents a substantial need, which we are addressing through our innovative compression technology.
Our ophthalmology pipeline features several programs addressing prevalent ocular unmet needs. For each program, we have designed compact, multifunctional therapeutic compounds poised to transform the clinical landscape. Our lead program is expected to enter clinical trials in 2026, marking a significant milestone in our commitment to revolutionizing ophthalmic treatment.
Target multiple pathways
Major ocular indications involve multiple pathways, driving the need for multi-specific or combination therapeutic approaches
With a single molecule
The only ways to effectively deliver biologics and gene therapies to the posterior eye are invasive, making it crucial to load all therapeutic functions on a single molecule
Protein therapies must be within a size window to effective diffuse to the posterior eye or penetrate into the target compartment.
Vectorized therapies must be <4.5Kbp to fit into AAV